Zobrazeno 1 - 10
of 71
pro vyhledávání: ''
Autor:
Salvatore Siena, Daniel Moya-Rull, Andrea Sartore-Bianchi, Emanuele Rausa, Annalisa Petrelli, Annunziata Gloghini, Brian M. Alexander, Daniela Conticelli, Asa Dahle-Smith, Sara Erika Bellomo, Filippo Pietrantonio, J. Lee, Siraj M. Ali, Giovanni Sgroi, Vincent A. Miller, Federica Morano, Salvatore Corallo, Uberto Fumagalli, Silvia Giordano, Maria Di Bartolomeo, Caterina Marchiò, Giovanni de Manzoni, Anna Sapino, Antonino Sottile, Stefano De Pascale, Gian Luca Baiocchi, Laura D'Errico, Silvia Marsoni, Rossella Reddavid, Simona Corso, Michele Prisciandaro, Stefania Durando, Zosia Miedzybrodzka, Cristina Migliore, Alexa B. Schrock, Russell D. Petty, Maria Apicella, Jeffrey S. Ross, Maurizio Degiuli, Sarah Molfino, Maria Bencivenga, Stefano Ughetto
Publikováno v:
Clinical Cancer Research. 27:3126-3140
Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomi
Autor:
Philipp Lohneis, Jana Käthe Striefler, Hendrik Bläker, Uwe Pelzer, Marcus Bahra, Carsten Denkert, Frederick Klauschen, Jan Budczies, Bruno Valentin Sinn, Denise Treue, U. Keilholz, Helmut Oettle, Hanno Riess, Marianne Sinn, Rosa Schmuck, Sven Bischoff, Frederik Damm
Publikováno v:
Clinical Cancer Research. 26:3732-3739
Purpose: We performed next-generation sequencing (NGS) in the CONKO-001 phase III trial to identify clinically relevant prognostic and predictive mutations and conducted a functional validation in The Cancer Genome Atlas (TCGA) sequencing data. Exper
Autor:
Max M. Quinn, Xiaoen Wang, Cyril H. Benes, Ashley A. Merlino, Qingsong Liu, Yuyang Li, Peng Gao, Kwok-Kin Wong, Nathanael S. Gray, Feiyang Liu, Fei Li, Yan Liu
Publikováno v:
Cancer Research. 77:5068-5076
Cells lacking the tumor suppressor gene LKB1/STK11 alter their metabolism to match the demands of accelerated growth, leaving them highly vulnerable to stress. However, targeted therapy for LKB1-deficient cancers has yet to be reported. In both Kras/
Autor:
Finn Cilius Nielsen, Olga Oestrup, Ulrik Lassen, Hans Skovgaard Poulsen, Petra Hamerlik, Jane Skjøth-Rasmussen, Christina Westmose Yde, Dorte Schou Noeroexe
Publikováno v:
Cancer Research. 81:444-444
Introduction: Glioblastoma (GBM) is a heterogenous cancer with a high degree of intratumoral subclonality. We foresee that future treatment will be a combination of non-targeted and targeted therapies against molecular features of each patient. In or
Autor:
Maura N. Dickler, A. Cervantes, Heidi Savage, T. R. Wilson, Cristina Saura, Ian E. Krop, Donald A. Richards, Marcos Vinicius Silva Oliveira, Huan Jin, Thomas J Stout, J. Baselga
Publikováno v:
Cancer Research. 77:P6-12
Background: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in hormone receptor (HR)-positive breast cancer (BC), with activating mutations of PIK3CA detected in ~35–45% of patients (pts). Acquired mutations in the ESR1
Autor:
Giselle Singer, Ayush Chandra, Rui Chang, Sharon Rose, Branden Lau, Jaya Sarin Pradhan, Larisa J. Geskin, Michael Moore, Megan H. Trager, Yvonne M. Saenger, Margaret Bogardus, Kuixi Zhu, Robyn D. Gartrell-Corrado, Emanuelle M. Rizk, Ben Fullerton, Gary Goldenbery
Publikováno v:
Cancer Immunology Research. 9:PO063-PO063
Background: The presence of actinic keratoses (AKs) increases a patient’s risk of developing squamous cell carcinoma (SCC) by greater than six-fold. It is difficult to predict which AKs will progress to become SCC, and topical treatments such as im
Autor:
Tanios Bekaii-Saab, Errin Samuelsz, Daniel H. Ahn, Afsaneh Barzi, Maya Ridinger, Mark G. Erlander, Heinz-Josef Lenz
Publikováno v:
Cancer Research. 80:CT235-CT235
Background: Chemotherapy in combination with targeted agents are standard-of-care options for patients for mCRC with response rates >50% in first line. In the second line setting, efficacy of chemotherapy and targeted agents are much lower with respo
Autor:
Lao H. Saal, Jari Häkkinen, Christer Larsson, Cecilia Hegardt, Anna Ehinger, Sofia Gruvberger, Malin Dahlgren, Christian Brueffer, Anthony M. George, Johan Vallon-Christersson, Åke Borg, Sergii Gladchuk, Martin Malmberg, Yilun Chen, Niklas Loman, Lisa Rydén
Publikováno v:
Cancer Research. 80:CT074-CT074
Background: More than three-quarters of primary breast cancers are positive for estrogen receptor alpha (ER; encoded by the gene ESR1), the most important factor for directing anti-estrogenic endocrine therapy. Although mutation in ESR1 is known as a
Autor:
William J. Irvin, William T. Barry, Eric P. Winer, Sara M. Tolaney, Chau T. Dang, Brandelyn N. Pitcher, Charles M. Perou, Lisa A. Carey, Elaine R. Mardis, Matthew D. Wilkerson, Clifford A. Hudis, Katherine A. Hoadley, Ian E. Krop, Donald A. Berry, Norah Lynn Henry, Joel S. Parker
Publikováno v:
Cancer Research. 75:S3-06
Background: In CALGB 40601, the HER2-Enriched (HER2-E) molecular subtype had significantly higher pathologic complete response (pCR) rates regardless of treatment arm (single HER2-targeting with T+L or T+H, dual targeting with T+H+L) (Carey et al, AS
Autor:
Alexandra M. Ward, Marek Kimmel, Heath D. Skinner, Thomas J. Ow, Ameeta A. Patel, Thomas O. McDonald, David M. Neskey, Paolo Bossi, Teng-Kuei Hsu, Jeffrey N. Myers, Mei Zhao, Federica Perrone, Abdullah A. Osman, Panagiotis Katsonis, Adel K. El-Naggar, Marcus V. Ortega Alves, Curtis R. Pickering, Erich M. Sturgis, Stephanie C. Hicks, Merrill S. Kies, Lisa Licitra, Olivier Lichtarge, Mitchell J. Frederick
Publikováno v:
Cancer Research. 75:1205-1215
TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the cu